TherapeuticsMD (TXMD) Short term Debt (2011 - 2022)
TherapeuticsMD (TXMD) posted Short term Debt of $93.6 million for Q3 2022, up 3.11% on a QoQ basis from $90.8 million in Q2 2022, and up 524.01% year-over-year from $15.0 million in Q3 2021.
TherapeuticsMD (TXMD) Short term Debt (2011 - 2022) Analysis & Trends
TherapeuticsMD's Short term Debt history runs 4 years deep, the most recent figure standing at $93.6 million for Q3 2022.
- Quarterly Short term Debt rose 524.01% year-over-year to $93.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $93.6 million (up 524.01% YoY) and the FY2021 annual result came in at $188.3 million, changed N/A from the prior year.
- Short term Debt was $93.6 million for Q3 2022 at TherapeuticsMD, up from $90.8 million in the prior quarter.
- Across five years, Short term Debt topped out at $202.9 million in Q1 2022 and bottomed at $5.0 million in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | TherapeuticsMD | 280,159.99 | -8.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 93.60 Mn |
| Jun 30, 2022 | 90.78 Mn |
| Mar 31, 2022 | 202.86 Mn |
| Dec 31, 2021 | 188.27 Mn |
| Sep 30, 2021 | 15.00 Mn |
| Jun 30, 2021 | 10.00 Mn |
| Mar 31, 2021 | 5.00 Mn |
| Mar 31, 2013 | 100,000.00 |
| Dec 31, 2011 | 2.15 Mn |